Coherus Oncology, Inc. Common Stock (CHRS)

• Market cap: $99.1M
• 1 day: -3.63%
• 5 days: -10.39%
• 1 month: -7.68%
• 3 months: -14.47%
• 6 months: -52.69%
• Year to date: -45.59%
• 1 year: -57.21%
• 5 years: -95.44%
• 10 years: -97.14%
• Sector: Healthcare
• Industry: Biotechnology

About: Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.

Employees: 221

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

158% more call options, than puts

Call options by funds: $173K | Put options by funds: $67K

25% more repeat investments, than reductions

Existing positions increased: 40 | Existing positions reduced: 32

3.37% less ownership

Funds ownership: 56.94% [Q4 2024] → 53.57% (-3.37%) [Q1 2025]

5% less funds holding

Funds holding: 122 [Q4 2024] → 116 (-6) [Q1 2025]

24% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 17

45% less capital invested

Capital invested by funds: $90.5M [Q4 2024] → $50.1M (-$40.4M) [Q1 2025]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $1.05 38% upside
• Avg. target: $4.03 428% upside
• High target: $7 819% upside

2 analyst ratings

• positive: 1 50%
• neutral: 1 50%
• negative: 0 0%

HC Wainwright & Co. Douglas Tsao	819% upside $7	Buy Reiterated	29 Apr 2025
UBS Ashwani Verma	38% upside $1.05	Neutral Maintained	24 Apr 2025